SVRA — Savara Inc. Stock Price, Chart & AI Report

Positive Mar 6, 2026 • 21:05 UTC Benzinga • Business Wire

Savara Provides Regulatory Update on the MOLBREEVI* Development Program in Autoimmune Pulmonary Alveolar Proteinosis (Autoimmune PAP)

Savara Inc. announced it received a Day 74 Letter from the FDA indicating no Advisory Committee meeting is planned for MOLBREEVI's Biologics License Application, with a PDUFA target action date of August 22, 2026. The company has submitted a Marketing Authorization Application to the European Medicines Agency and remains on track to submit to the UK's MHRA by end of Q1 2026. MOLBREEVI, a recombinant GM-CSF treatment for autoimmune PAP, has received Fast Track and Breakthrough Therapy designations from the FDA.

SVRA MOLBREEVI autoimmune PAP FDA approval regulatory update rare respiratory disease GM-CSF BLA

Sentiment note

The company received positive regulatory feedback with no Advisory Committee meeting required, indicating FDA confidence in the application. Successful submissions to EMA and on-track UK submission demonstrate progress across multiple regulatory jurisdictions. MOLBREEVI has received multiple designations (Fast Track, Breakthrough Therapy, Orphan Drug) supporting its development pathway for a first-in-class treatment in an unmet medical need.

Neutral Mar 4, 2026 • 21:05 UTC Benzinga • Business Wire

Savara Announces Participation in 2026 Citizens Life Sciences Conference

Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company, announced that its management team will participate in a fireside chat at the 2026 Citizens Life Sciences Conference on March 11th in Miami, FL. The company is focused on rare respiratory diseases with its lead program MOLBREEVI, a recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).

SVRA Savara Inc. biopharmaceutical rare respiratory diseases MOLBREEVI Phase 3 autoimmune PAP Citizens Life Sciences Conference

Sentiment note

The announcement is a routine corporate event participation disclosure. While it demonstrates continued progress and investor engagement activities, the news itself does not contain material clinical, regulatory, or financial developments that would warrant a positive or negative sentiment. It is a standard conference participation announcement.

Positive Feb 4, 2026 • 21:05 UTC Benzinga • Business Wire

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara Inc. (NASDAQ: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that its management team will participate in one-on-one meetings and fireside chats at two upcoming investor healthcare conferences. The company's lead program, MOLBREEVI, is a recombinant human GM-CSF in Phase 3 development for autoimmune pulmonary alveolar proteinosis (autoimmune PAP).

SVRA biopharmaceutical rare respiratory diseases clinical stage investor conference MOLBREEVI autoimmune PAP Phase 3

Sentiment note

The company is advancing its lead program MOLBREEVI to Phase 3 development and actively engaging with investors at healthcare conferences, demonstrating progress in clinical development and investor relations activities for a rare disease treatment.

Negative Jan 24, 2026 • 16:38 UTC GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

SAVARA INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Savara, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Law firm Bragar Eagel & Squire is investigating Savara, Inc. for potential breach of fiduciary duties by its board of directors. The investigation concerns allegations that Savara failed to disclose that its MOLBREEVI BLA lacked sufficient information regarding chemistry, manufacturing, and controls, making FDA approval unlikely. On May 27, 2025, the FDA issued a refusal to file letter, causing Savara's stock to plummet 31.69% to $1.94 per share. The class action covers the period from March 7, 2024 to May 23, 2025.

SVRA class action lawsuit fiduciary duty breach FDA refusal to file MOLBREEVI BLA stock price decline disclosure failure shareholder investigation

Sentiment note

The company faces a class action investigation for allegedly failing to disclose material information about regulatory deficiencies in its lead drug candidate MOLBREEVI. The subsequent FDA rejection letter resulted in a severe 31.69% stock price decline, indicating significant investor losses and loss of confidence in the company's management and disclosure practices.

Positive Dec 17, 2025 • 13:05 UTC Benzinga • Business Wire

Savara Announces Participation in the 44th Annual J.P. Morgan Healthcare Conference

Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, will present at the 44th Annual J.P. Morgan Healthcare Conference. The company's lead program, MOLBREEVI, is a Phase 3 development treatment for autoimmune pulmonary alveolar proteinosis.

SVRA biopharmaceutical respiratory diseases healthcare conference MOLBREEVI pulmonary alveolar proteinosis

Sentiment note

The company is actively presenting at a major healthcare conference and advancing a lead program in Phase 3 development, indicating progress and potential growth

Neutral Nov 20, 2025 • 21:05 UTC Benzinga • Business Wire

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, will participate in upcoming healthcare investor conferences, hosting one-on-one meetings and fireside chats.

SVRA healthcare conferences respiratory diseases biotechnology

Sentiment note

The company is presenting at investor conferences, which suggests ongoing business activities and potential investor engagement, but no significant positive or negative developments are highlighted

Negative Nov 7, 2025 • 07:22 UTC Benzinga • Prnewswire

SVRA Investors Have Opportunity to Lead Savara Inc. Securities Fraud Lawsuit with the Schall Law Firm

The Schall Law Firm is pursuing a class action lawsuit against Savara Inc. for allegedly making false and misleading statements about their BLA (Biologics License Application) for MOLBREEVI, which was deemed insufficient by the FDA and likely to require additional capital.

SVRA securities fraud lawsuit BLA FDA investor rights

Sentiment note

The company is accused of providing inadequate information to the FDA for their drug application, making false statements to the market, and potentially causing investor financial losses

Negative Nov 6, 2025 • 01:57 UTC GlobeNewswire Inc. • Rosen Law Firm

SVRA DEADLINE: ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

Rosen Law Firm alerts Savara Inc. investors about a securities class action lawsuit regarding potential misleading statements about a clinical trial's regulatory approval process, with a November 7, 2025 lead plaintiff deadline.

SVRA securities class action FDA clinical trial regulatory approval

Sentiment note

The lawsuit alleges the company made false or misleading statements about its MOLBREEVI clinical trial's Biologics License Application, suggesting potential regulatory challenges and potential need for additional capital raising

Positive Nov 3, 2025 • 21:05 UTC Benzinga • Business Wire

Savara Announces Participation in Upcoming Investor Healthcare Conferences

Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, will participate in upcoming healthcare investor conferences, hosting meetings and fireside chats to discuss their lead program MOLBREEVI.

SVRA healthcare conferences respiratory diseases biotechnology investor relations

Sentiment note

The company is actively engaging with investors, showcasing its lead program MOLBREEVI in Phase 3 development, and demonstrating management's experience in rare respiratory diseases

Negative Nov 2, 2025 • 23:47 UTC GlobeNewswire Inc. • Rosen Law Firm

SVRA DEADLINE: ROSEN, HIGHLY RANKED INVESTOR RIGHTS COUNSEL, Encourages Savara Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

Rosen Law Firm is alerting Savara Inc. investors about a securities class action lawsuit regarding potential misleading statements about a clinical trial's regulatory approval process.

SVRA securities class action FDA clinical trial regulatory approval

Sentiment note

The lawsuit alleges the company made false or misleading statements about its MOLBREEVI clinical trial's Biologics License Application, suggesting potential regulatory challenges and potential need for additional capital raising

Negative Oct 30, 2025 • 23:32 UTC GlobeNewswire Inc. • Rosen Law Firm

SVRA FINAL DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Savara Inc. Investors to Secure Counsel Before Important November 7 Deadline in Securities Class Action– SVRA

Rosen Law Firm alerts Savara Inc. investors about a securities class action lawsuit regarding potential misleading statements about a clinical trial's Biologics License Application and FDA approval timeline.

SVRA securities class action FDA clinical trial investor rights

Sentiment note

The lawsuit alleges the company made false or misleading statements about its MOLBREEVI clinical trial, FDA approval prospects, and potential need for additional capital, suggesting significant regulatory and financial challenges

Negative Oct 30, 2025 • 17:46 UTC GlobeNewswire Inc. • Law Offices Of Howard G. Smith

DEADLINE ALERT for QMCO, TROX, SVRA, FLYE: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions

Law firm alerts investors about potential securities fraud class action lawsuits for four companies, highlighting alleged misleading statements and financial irregularities during specific time periods.

QMCO TROX SVRA FLYE securities fraud class action investor lawsuit financial misrepresentation

Sentiment note

Suggested to have insufficient regulatory documentation for drug approval and potential capital raising needs